American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru
American Clinical Research Services (“ACRS”) has announced the acquisition of Clinical Site Services (“CSSi”) and Patient Advertising Guru (“PAG”). The acquisition of the two previously merged companies demonstrates ACRS’s focus on inclusive patient centric solutions for clinical development. Both Chris Trizna (CSSi) and Evan Brett (PAG) remain as co-Presidents, joining the ACRS leadership team.
Clinical Site Services is a provider of customized, full-service site centric patient recruitment solutions. CSSi’s Local Enrollment Specialists are former study coordinators, located across the globe, that support sites to generate referrals from within the site, their community, advocacy groups, and local medical practitioners.
Patient Advertising Guru is a niche provider of advertising, providing creative development, media buying, and referral tracking services. PAG is also the creator of Research Study Rockstar, a social media resource for patient recruitment.
Both CCSi and PAG have experience servicing a range of therapeutic areas, including oncology, CNS, metabolic, and women’s health, across 50+ countries.
Reference
Latticework Capital Management’s American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru. (2023, May 9). Business Wire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
